The Impact of Empagliflozin on Inflammatory Markers in Adults with Type 2 Diabetes: A Retrospective Cohort

Overview

Journal Med J Islam Repub Iran

Date 2025 Jan 9

PMID 39781318

Authors

Hossein Samadanifard

Zahra Barati

Amir Hossein Ghanooni

Delaram Eskandari

Amir Ziaee

Haleh Chehrehgosha

Fatemeh Sarv

Shadi Zahraei

Affiliations

Soon will be listed here.

Abstract

Background: Inflammation plays a significant role in the development and progression of type 2 diabetes (T2D). Empagliflozin, an SGLT2 inhibitor, has shown some anti-inflammatory effects in patients with T2D. This study aimed to evaluate the impact of empagliflozin on some inflammatory markers in T2D.

Methods: This retrospective single-arm cohort study included 40 patients with T2D who were treated with empagliflozin. Inflammatory markers such as serum level of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and serum albumin were evaluated at baseline and 12 weeks after empagliflozin treatment. Statistical analysis used paired samples t test, and the statistically significant level was considered < 0.05.

Results: After 12 weeks, a significant reduction was found in ESR (17.75 ± 15.7 mm/hr to 14.72 ± 10.93 mm/hr; = 0.025). However, the decrease in hs-CRP did not reach significance ( = 0.936). NLR did not show a significant reduction ( = 0.962), but there was a trend toward a significant decrease in PLR (107 ± 33 to 100 ± 35; = 0.053). The neutrophil count did not change significantly ( = 0.247), but the lymphocyte count significantly increased (2.43 ± 7.85 to 2.57 ± 7.45 109/l; = 0.014). Serum albumin showed a significant increase (42.8 ± 3.4 to 45.6 ± 3.2 g/l; < 0.001), indicating a decrease in inflammation.

Conclusion: Empagliflozin showed anti-inflammatory effects by reducing ESR and PLR and increasing serum albumin and lymphocyte count in adults with T2D. Monitoring inflammatory markers can serve as an indicator of treatment effectiveness in T2D patients.

References

Reppo I, Jakobson M, Volke V . Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes. Int J Mol Sci. 2023; 24(6). PMC: 10054691. DOI: 10.3390/ijms24065714. View

Theofilis P, Sagris M, Oikonomou E, Antonopoulos A, Siasos G, Tsioufis K . The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents. Int Immunopharmacol. 2022; 111:109080. DOI: 10.1016/j.intimp.2022.109080. View

Rohm T, Meier D, Olefsky J, Donath M . Inflammation in obesity, diabetes, and related disorders. Immunity. 2022; 55(1):31-55. PMC: 8773457. DOI: 10.1016/j.immuni.2021.12.013. View

Soeters P, Wolfe R, Shenkin A . Hypoalbuminemia: Pathogenesis and Clinical Significance. JPEN J Parenter Enteral Nutr. 2018; 43(2):181-193. PMC: 7379941. DOI: 10.1002/jpen.1451. View

Gohari S, Reshadmanesh T, Khodabandehloo H, Karbalaee-Hasani A, Ahangar H, Arsang-Jang S . The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial. Diabetol Metab Syndr. 2022; 14(1):170. PMC: 9669535. DOI: 10.1186/s13098-022-00951-5. View

Goodnough L, Skikne B, Brugnara C . Erythropoietin, iron, and erythropoiesis. Blood. 2000; 96(3):823-33. View

Hattori S . Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance. Diabetol Metab Syndr. 2018; 10:93. PMC: 6299593. DOI: 10.1186/s13098-018-0395-5. View

Elimam H, Abdulla A, Taha I . Inflammatory markers and control of type 2 diabetes mellitus. Diabetes Metab Syndr. 2019; 13(1):800-804. DOI: 10.1016/j.dsx.2018.11.061. View

Andersen C, Omar M, Glenthoj A, El Fassi D, Moller H, Lindholm Kurtzhals J . Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial. Eur J Heart Fail. 2022; 25(2):226-234. DOI: 10.1002/ejhf.2735. View

10.

Balcioglu Y, Kirlioglu S . C-Reactive Protein/Albumin and Neutrophil/Albumin Ratios as Novel Inflammatory Markers in Patients with Schizophrenia. Psychiatry Investig. 2020; 17(9):902-910. PMC: 7538240. DOI: 10.30773/pi.2020.0185. View

11.

Benedikt M, Mangge H, Aziz F, Curcic P, Pailer S, Herrmann M . Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial. Cardiovasc Diabetol. 2023; 22(1):166. PMC: 10324245. DOI: 10.1186/s12933-023-01904-6. View

12.

Gasparyan A, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas G . The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases. Ann Lab Med. 2019; 39(4):345-357. PMC: 6400713. DOI: 10.3343/alm.2019.39.4.345. View

13.

Iannantuoni F, de Maranon A, Diaz-Morales N, Falcon R, Banuls C, Abad-Jimenez Z . The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. J Clin Med. 2019; 8(11). PMC: 6912454. DOI: 10.3390/jcm8111814. View

14.

S Ellulu M, Samouda H . Clinical and biological risk factors associated with inflammation in patients with type 2 diabetes mellitus. BMC Endocr Disord. 2022; 22(1):16. PMC: 8740444. DOI: 10.1186/s12902-021-00925-0. View